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CIMS Balloon Pump : A Novel Left Ventricle Assist Device (LVAD)
5) Method
A prototype balloon pump was developed - the outer body has a hard casing with a flexible 
silicone membrane inside it . The CIMS balloon pump prototype is placed just distal of the 
aortic valve in a human mock circulatory loop (MCL). 
The MCL is capable of simulating a variety of heart 
condition by adjusting left ventricle (LV) silicone sack 
contraction and peripheral resistance.  
Other than systemic circulation simulating LV and aortic
flow, it is also equipped with left coronary artery (LCA) 
circulation. The LCA tube is placed just distal of the aortic 
valve and consists of a flow sensor, compliance syringe,
pressure transducer and systolic resistor to simulate systolic 
compression of myocardium affecting the LCA.  
The CIMS balloon pump  is connected to an IABP driver 
console. Once HF condition is set on the MCL the  CIMS 
balloon pump is activated at 1:1 ratio i.e. at every heart 
beat triggered at the dicrotic notch. Data was taken for 
non-assisted flow and assisted 
flow for 40 seconds. Several 
parameters were measured and 
student t-test was used  to 
determine the significance 
of flow augmentation. 
7) Conclusion
From the results it is evident that a device placed in the ascending aorta decreases  the 
heart’s load and increases flow output into coronary and peripheral circulations.  The CIMS 
balloon pump increases aortic flowrate by only 0.22 L/min, but succeeds in lowering 
afterload resistance which the heart must overcome to eject blood in systole and in 
increasing the blood supply to the myocardium thus improving cardiac dynamics in both 
systole and diastole.
8) Future Work
Further testing will be carried out to investigate the effect of  balloon pump compliance on 
flow augmentation. It is hypothesized that increased balloon pump compliance will give a 
more favourable haemodynamic response especially on systemic perfusion and decrease 
afterload.
6) Result
The preliminary results using a CIMS balloon pump housing are very promising.  A graph of 
aortic pressure, aortic flowrate and left coronary flowrate is presented in Figures 6 and 7 
respectively.  The numerical values ( with standard deviations) for main parameters of 
interest appear in Table 1.
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1) Background
In the UK, death from heart failure (HF) is at 24,000 in 2001, while new cases of HF is 
estimated to be at 63,500 every year. The probability of death within one year of diagnosis is 
40%, if untreated (1). 
Heart failure treatment varies from lifestyle change, pharmacological treatment or surgical 
intervention. For advanced stages HF patients, heart transplant is the gold standard 
treatment. However, since donors are scarce resulting only 3000 operation/year worldwide, 
the next best treatment is mechanical heart assist device.
3)Chronic Intermittent Mech. Support (CIMS)
It has been reported that with prolonged mechanical support and pharmacological 
treatment a specific cohort of patient is able to develop and sustain HF reversal (3). 
Chronic Intermittent Mechanical Support (CIMS) is a modality treatment that targets a 
specific cohort of patient suffering Dilated Cardiomyopathy (DC) or congestive heart failure 
(CHF). The treatment focuses on treating the patient by lowering the load on the patient’s 
heart and increasing oxygen supply to the myocardium. It is designed for continuous 
activation, although it can be turned on and off depending on the patient’s condition. It will 
be placed in the ascending aorta, thus being a left ventricle assist device (LVAD). CIMS 
advantages are:
•Easy to implant
•Long term usage
•Ambulatory (easy to carry around)
•Can be turned on/off  & console removed
•Promoting heart recovery
•Relatively cheaper than IRBP
•Earlier (less aggressive) intervention.
The CIMS uses balloon pump, a displacement-type 
heart assist device counterpulsed like an
Intra Aortic Balloon Pump (IABP). 
CIMS is actuated by a percutaneous gas driveline 
connected to a portable console and battery pack. 
2) Aim & Objectives
The aim of this study is to develop mechanical heart assist device specifically for left ventricle 
i.e. left ventricular assist device (LVAD) system that is able to restore heart health by reverse 
remodelling (self healing process). It is hypothesized reverse remodelling can be achieved by 
decreasing load faced by heart and increasing coronary perfusion. As such, objectives of this 
study are
•To develop a prototype of balloon pump
•To determine ventricular work reduction
•To optimize of balloon pump design, including for in-vivo experiment
In this poster, the first two objectives’ result is presented.
4) IABP-the benchmark device
Intra aortic balloon pump (IABP) is a short term displacement type mechanical heart assist 
device used before or during a cardiac operation to increase coronary artery perfusion and 
unload the left ventricle.
IABP is placed in the descending aorta around 10 to 20mm distal of the subclavian artery. –
usually via femoral artery cannulation. It is counterpulsed to increase aortic pressure during 
diastole; the balloon pump is inflated after the dicrotic notch is detected and deflated just 
before the start of the next systole. Example of counterpulsation is as per Figure 2.
A major drawback due to femoral access, IABP recipients are bed bound and can suffer 
reduced perfusion of the cannulated leg. 
Figure1: CIMS in concept
Figure 2: Counterpulsation effect on aortic pressure  and activation of IABP
Figure 4 : Balloon Pump Prototype
Figure 6: Aortic Pressure Waveform with augmentation Figure7: Aortic and coronary flowrate augmentation
Table 1: Haemodynamics reponse due to balloon pump counterpulsation
) Background ) im & Objective
) r ic Intermittent Mech. Support (CIMS) ) IABP – t  chmark device
) ethod ) Result
) Discussion & Conclusion ) Future Work
Figure 3: Mock Circulatory Loop with 
an IABP driver console
Cardiac 
Output 
(CO) 
[L/min]
Left Coronary 
Artery 
Flowrate
[mL/min]
Aortic End 
Diastolic 
Pressure 
(Afterload) 
[mmHg]
LV Hydraulic 
Work [Watt]
Non-assisted 3.18 ± 0.03 65.4 ± 0.52 51 ± 0.52 0.5 ± 0.03
Assisted 3.4 ± 0.08 72.5 ± 0.87 48 ± 1.16 0.44 ± 0.08
Percentage of 
difference
6.71% 10.82% -6.01% -11.38%
p value <0.001 <0.001 <0.001 <0.001
Figure 5: Concept design of in-vivo balloon pump 
